MA28029A1 - Double helice d'arn d'interference possedant des extremites franches et des modifications en 3' - Google Patents

Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'

Info

Publication number
MA28029A1
MA28029A1 MA28861A MA28861A MA28029A1 MA 28029 A1 MA28029 A1 MA 28029A1 MA 28861 A MA28861 A MA 28861A MA 28861 A MA28861 A MA 28861A MA 28029 A1 MA28029 A1 MA 28029A1
Authority
MA
Morocco
Prior art keywords
aryl
alkyl
propeller
changes
double
Prior art date
Application number
MA28861A
Other languages
English (en)
Inventor
Jan Weiler
Jonathan Hall
Jean-Charles Bologna
Francois Jean-Charles Natt
Robert Haener
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28029A1 publication Critical patent/MA28029A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur des composés d'ARN double brin pourvus d'au moins une extrémité franche comprenant au moins une extrémité 3' de formule (I). dans laquelle X représente O ou S; R1 et R2 représentent, indépendamment, OH, NH2, SH, alkyle, aryle, alkyl-aryle, aryl-alkyle, où alkyle, aryle, alkyl-aryle, aryl-alkyle peuvent être substitués par des hétéro-atomes additionnels et des groupes fonctionnels; de préférence, un hétéro-atome est sélectionné dans le groupe de N, O ou S ou un groupe fonctionnel est sélectionné dans le groupe OH, NH2, SH, l'acide carboxylique ou un ester; ou R| et R2 peuvent être de la formule Y-Z dans laquelle Y représente O. N, S et Z représente H, alkyle, aryle, alkyl-aryle, aryl-alkyle, où alkyle, aryle, alkyl-aryle, aryl-alkyle peuvent être substitués par des hétéro-atomes additionnels, de préférence un hétéro-atome sélectionné dans le groupe de N, O ou S. Dans la formule de cette invention, l'ARN double brin induit une interférence ARN. Les modifications préférées à l'extrémité 3' sont: phosphate, phosphorothioate, ribonucléoside abasique. hydroxypropyle, phosphodiester.
MA28861A 2003-08-28 2006-03-08 Double helice d'arn d'interference possedant des extremites franches et des modifications en 3' MA28029A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49851403P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
MA28029A1 true MA28029A1 (fr) 2006-07-03

Family

ID=34272687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28861A MA28029A1 (fr) 2003-08-28 2006-03-08 Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'

Country Status (21)

Country Link
US (2) US20070203084A1 (fr)
EP (3) EP1660657A1 (fr)
JP (2) JP2007503803A (fr)
KR (3) KR20110007263A (fr)
CN (2) CN101914533B (fr)
AU (1) AU2004269150C1 (fr)
BR (1) BRPI0413146A (fr)
CA (1) CA2536333C (fr)
CO (1) CO5680494A2 (fr)
EC (1) ECSP066388A (fr)
IL (1) IL173565A (fr)
IS (1) IS8358A (fr)
MA (1) MA28029A1 (fr)
MX (1) MXPA06002216A (fr)
NO (1) NO20061345L (fr)
NZ (1) NZ545360A (fr)
RU (2) RU2399671C2 (fr)
SG (1) SG152279A1 (fr)
TN (1) TNSN06065A1 (fr)
WO (1) WO2005021749A1 (fr)
ZA (1) ZA200601003B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG152279A1 (en) 2003-08-28 2009-05-29 Novartis Ag Interfering rna duplex having blunt-ends and 3æ-modifications
GB0608838D0 (en) * 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008049078A1 (fr) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Molécules d'acide nucléique ouvertes ou coupées et leurs utilisations
JP4900943B2 (ja) * 2006-12-25 2012-03-21 独立行政法人産業技術総合研究所 ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ
CA2692503C (fr) 2007-07-05 2013-09-24 Novartis Ag Arndb pour le traitement de l'infection virale
WO2009118300A1 (fr) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement du cancer par régulation à la baisse de frizzled-4 et/ou frizzled-1
WO2010100247A1 (fr) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Nouvelle thérapie contre l'anxiété
EP2241323A1 (fr) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascine-W et cancers du cerveau
EP2292266A1 (fr) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Traitement du cancer en modulant la copine III
WO2011036118A1 (fr) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement du cancer par modulation de mex-3
WO2011045352A2 (fr) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Tyrosine kinase de la rate et cancers du cerveau
EP3434773A3 (fr) 2009-12-09 2019-04-17 Nitto Denko Corporation Modulation de l'expression de hsp47
KR101718297B1 (ko) 2009-12-18 2017-03-20 애로우헤드 리서치 코오포레이션 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
WO2011076807A2 (fr) 2009-12-23 2011-06-30 Novartis Ag Lipides, compositions lipidiques, et procédés d'utilisation associés
IN2012DN06588A (fr) 2010-02-10 2015-10-23 Novartis Ag
WO2011107586A1 (fr) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, ténascine-c et cancers du cerveau
WO2011131611A1 (fr) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation de xrn1
WO2011133876A2 (fr) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucléotides comprenant des nucléosides acycliques et abasiques, et analogues
CN102985544A (zh) 2010-04-23 2013-03-20 诺瓦提斯公司 治疗β-ENaC-相关疾病的有机组合物
WO2011154485A1 (fr) 2010-06-10 2011-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement du cancer par modulation de la kinase 3 stérile de mammifère de type 20
WO2012168259A1 (fr) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protéine tyrosine phosphatase de type non-récepteur 11 (ptpn11), et cancer du sein triple négatif
BR112014001396A2 (pt) * 2011-07-18 2017-02-21 Devgen Nv plantas resistentes a pragas de insetos
EP3521432A1 (fr) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Compositions organiques de traitement de maladies associées à hsf1
WO2013068431A1 (fr) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Traitement inédit contre les maladies neurodégénératives
WO2013068432A1 (fr) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Diagnostic précoce de maladies neurodégénératives
WO2013072392A1 (fr) 2011-11-15 2013-05-23 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Combinaison d'un inhibiteur de la phosphoinositide 3-kinase et d'un modulateur de la voie janus kinase 2 - transducteur de signal et activateur de transcription 5
WO2013102825A1 (fr) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 et cancer du sein
CA2860676A1 (fr) 2012-01-09 2013-07-18 Novartis Ag Compositions organiques pour traiter des maladies associees a la beta-catenine
EP2831112A1 (fr) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition de l'interleukine 8 et/ou de ses récepteurs cxcrl dans le traitement du cancer du sein surexprimant her2/her3
EP3272868A1 (fr) 2012-05-02 2018-01-24 Arrowhead Pharmaceuticals, Inc. Compositions organiques pour traiter des maladies associées à kras
DK2853597T3 (en) * 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
EP2869818A1 (fr) 2012-07-06 2015-05-13 Novartis AG Combinaison d'un inhibiteur de phosphoinositide 3-kinase et d'un inhibiteur de l'interaction il-8/cxcr
JP2016511256A (ja) 2013-02-28 2016-04-14 アローヘッド リサーチ コーポレイション Ｅｐａｓ１関連疾患を治療するための有機組成物
KR102144777B1 (ko) * 2013-06-19 2020-08-18 제이더블유중외제약 주식회사 결정형 메로페넴 삼수화물의 제조방법
WO2015019286A1 (fr) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research Nouvelle méthode de criblage pour le traitement de l'ataxie de friedreich
WO2015051135A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Compositions organiques destinées au traitement de maladies associées à l'hepcidine
US10519446B2 (en) 2013-10-04 2019-12-31 Novartis Ag Organic compounds to treat hepatitis B virus
WO2015051044A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Formats inédits pour composés organiques utiisables en interférence arn
WO2015051045A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Extrémités 3' pour agents arni destinés à être utilisés dans l'interférence arn
WO2015051366A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Formats inédits pour composés organiques utilisables en interférence arn
KR101696704B1 (ko) * 2013-12-17 2017-01-16 주식회사 인코드젠 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
WO2015189816A1 (fr) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research Nouveau traitement dirigé contre le virus de la grippe
WO2016001830A1 (fr) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combinaison d'un inhibiteur de braf v600e et d'un inhibiteur de mertk pour le traitement du mélanome
EP3169784B1 (fr) 2014-07-16 2020-06-10 Arrowhead Pharmaceuticals, Inc. Compositions d'arni pour le traitement de pathologies liées à l'apoc3
WO2016010840A1 (fr) 2014-07-16 2016-01-21 Novartis Ag Procédé d'encapsulation d'un acide nucléique dans une nanoparticule lipidique hôte
EP3191592A1 (fr) 2014-09-11 2017-07-19 Novartis AG Inhibition de prmt5 dans le traitement de maladies liées à une déficience en mtap
EP3197557A1 (fr) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats et cancer du sein
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
EP3302525A2 (fr) 2015-06-05 2018-04-11 Novartis AG Méthodes et compositions permettant de diagnostiquer, traiter et surveiller le traitement de troubles associés à une déficience en shank3
EP3368566A1 (fr) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Ténascine w et cancers du tractus biliaire
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
US9721645B1 (en) 2016-01-29 2017-08-01 Taiwan Semiconductor Manufacturing Company, Ltd. SRAM arrays and methods of manufacturing same
WO2018047148A1 (fr) 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
EP3535396A1 (fr) 2016-11-01 2019-09-11 Novartis AG Procédés et compositions pour améliorer l'édition de gènes
EP3655004A2 (fr) 2017-07-21 2020-05-27 Novartis AG Compositions et procédés permettant de traiter un cancer
MX2020002648A (es) 2017-09-11 2020-07-22 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la apolipoproteina c-iii (apoc3).
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
WO2024134502A1 (fr) 2022-12-20 2024-06-27 Novartis Ag Ligases d'arn double brin modifiées et leurs utilisations
WO2024134505A1 (fr) 2022-12-20 2024-06-27 Novartis Ag Procédé de ligature d'acide nucléique

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071510C (fr) 1989-10-24 2004-07-06 Chris A. Buhr Oligonucleotides modifies en 2'
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
IL104461A (en) 1992-01-22 2001-05-20 Hoechst Ag Analogs of oligonucleotide, their preparation and pharmaceutical preparations containing them
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
WO2002096927A2 (fr) * 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
WO2000044914A1 (fr) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2005019453A2 (fr) 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. Interference arn a mediation assuree par l'inhibition de genes au moyen de petit acide nucleique interferent (ansi) modifie chimiquement
US20050233329A1 (en) 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
WO2002081628A2 (fr) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
WO2003070918A2 (fr) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
ES2728168T3 (es) 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
EP1229134A3 (fr) 2001-01-31 2004-01-28 Nucleonics, Inc Utilisation de l'inhibition post-transcriptionnelle pour l'identification des séquences d'acides nucléiques qui modifient la fonction d'une cellule
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20070032441A1 (en) 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20090247606A1 (en) 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
DK1389637T3 (da) * 2002-08-05 2012-09-03 Silence Therapeutics Ag Interfererende RNA-molekyler med stumpe ender
ES2280826T5 (es) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
US20070270360A1 (en) * 2003-04-15 2007-11-22 Sirna Therapeutics, Inc. Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
EP1620544B1 (fr) 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. Agents modifies d'arni
EP1636385A4 (fr) 2003-06-24 2010-06-02 Mirus Bio Corp Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
SG152279A1 (en) 2003-08-28 2009-05-29 Novartis Ag Interfering rna duplex having blunt-ends and 3æ-modifications
EP1765847A4 (fr) 2004-05-27 2010-10-20 Alnylam Pharmaceuticals Inc Acide ribonucleique double brin resistant aux nucleases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20110007263A (ko) 2011-01-21
RU2010119292A (ru) 2011-12-10
RU2399671C2 (ru) 2010-09-20
IL173565A0 (en) 2006-07-05
ECSP066388A (es) 2006-08-30
CN1845993B (zh) 2010-06-23
MXPA06002216A (es) 2006-04-27
AU2004269150B2 (en) 2009-06-04
BRPI0413146A (pt) 2006-10-03
US20070203084A1 (en) 2007-08-30
ZA200601003B (en) 2007-04-25
IS8358A (is) 2006-03-17
WO2005021749A1 (fr) 2005-03-10
US8097716B2 (en) 2012-01-17
KR101059315B1 (ko) 2011-08-24
CA2536333C (fr) 2013-01-08
EP2338995A2 (fr) 2011-06-29
SG152279A1 (en) 2009-05-29
EP2489737A1 (fr) 2012-08-22
JP2011160796A (ja) 2011-08-25
RU2006109547A (ru) 2007-10-10
NZ545360A (en) 2009-06-26
CN101914533A (zh) 2010-12-15
AU2004269150C1 (en) 2010-11-18
AU2004269150A1 (en) 2005-03-10
CA2536333A1 (fr) 2005-03-10
NO20061345L (no) 2006-05-29
KR20080034046A (ko) 2008-04-17
CN101914533B (zh) 2013-06-19
EP2338995A3 (fr) 2012-01-11
CO5680494A2 (es) 2006-09-29
CN1845993A (zh) 2006-10-11
TNSN06065A1 (en) 2007-10-03
US20090192113A1 (en) 2009-07-30
JP2007503803A (ja) 2007-03-01
IL173565A (en) 2012-07-31
EP1660657A1 (fr) 2006-05-31
KR20060087531A (ko) 2006-08-02

Similar Documents

Publication Publication Date Title
MA28029A1 (fr) Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'
EP1010691A3 (fr) Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
ATE239752T1 (de) Pyrimidinderivate als markierte bindungspartner
ATE277066T1 (de) Bicyclonucleosid-analoga
CA2192824A1 (fr) Derives de l'acide pyridone-carboxylique, procedes de preparation connexe et agents anti-tumorals contenant ces derives
WO1999035157B1 (fr) Nouveaux derives d'erythromycine
BR9510207A (pt) Derivados de benzamidoxima processo para a sua preparação e fungicida para usa agricola e horticola
EP1884556A3 (fr) Compositions de carburant diesel contenant des espèces metalliques et des additifs détergents
JP2004537516A5 (fr)
KR850007975A (ko) 6-클로로벤즈아졸릴옥시아세트아미드의 제조방법
US4287191A (en) Novel salicylanilides and microbiocidal compositions and uses thereof
FR2786188B1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
EA200101100A1 (ru) Новые ароматические амиды, замещенные рибозой, способ их получения и их применение в качестве лекарств
RU2008112549A (ru) Сочетание биологически доступного метионина с по меньшей мере одним эфирным маслом
DK0455300T3 (da) Barbitursyrederivater med insekticid virkning
KR910007922A (ko) 벤즈옥사지닐-피라졸, 및 그의 제조방법 및 용도
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR900701779A (ko) 옥시란유도체 및 그것을 유효성분으로 하는 제초제
PT1016409E (pt) Composicao liofilizada esfingoglicolipidos e o processo para a sua preparacao
CA2118052A1 (fr) Derives du n-(aminosubstitue)pyrrole, leur procede de preparation et compositions herbicides
BR9908960A (pt) Amino guanidinas cìclicas
HUP0301561A2 (hu) Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására
KR900018005A (ko) 사이클로프로파노일아미노산 아미드 유도체
KR970019858A (ko) 이미노아세테이트를 포함하는 신규 티아졸 화합물, 그의 제조방법 및 유효성분으로서 그를 함유하는 살균제 조성물
PL292899A1 (en) Fodder compositions for use in farming animals as well as compositions in the form of fodder additives, premixtures and ready-to-use fodder containing novel isoquinoline derivatives and method of obtaining such compositions